Citi initiated coverage of Apogee Therapeutics (APGE) with a Buy rating and $95 price target Healthcare policy remains a key biopharma sector uncertainty but major economic worries have underscored the defensive attributes of biotech, the analyst tells investors in a research note. The firm says that despite near-term “choppiness,” a “barbell approach” to the sector still makes sense with higher-growth large caps likely able to absorb potential policy headwinds and catalyst-driven small-cap biotechs being insulated from macro uncertainties. Citi’s preferred smaller caps are focused on unmet medical needs, have differentiated research and development platforms or are “clean growth stories.” The firm highlights Apogee, Avidity, and Kymera as favorites.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APGE:
- Strong Buy Recommendation for Apogee Therapeutics Driven by Promising Clinical Data and Strategic Pipeline Developments
- Apogee Therapeutics: Buy Rating Backed by Promising Data and Strong Financial Position
- Optimistic Buy Rating for Apogee Therapeutics Driven by Promising Clinical Trial Developments
- Apogee Therapeutics Reports 2024 Financial Results and Pipeline Progress
- Apogee Therapeutics price target raised to $116 from $110 at Guggenheim